This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Evidence-Based Medicine  • Neoplasms  • Alert me on articles by topic

Neal Ready, MD; Martin A. Weinstock, MD, PhD

Arch Dermatol. 2003;139:1203-1204.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials
Lens MB, Dawes M, Goodacre T, Newton-Bishop JA
Arch Surg.
2002;137:458-461

Question: Does elective lymph node dissection (ELND) decrease overall mortality in patients with melanoma and no clinically detectable regional metastases?

Data Sources: MEDLINE (1966-February 2001) and EMBASE (1974-February 2001) using the recommended Cochrane Collaboration search strategy with the MeSH (medical subject headings) terms "melanoma" and "elective lymph node." Data were also gathered from selected conference proceedings, the Controlled Trials Register from the Cochrane Library (issue 4, 2000), and unpublished data from contacted authors.

Study Selection: Randomized controlled trials comparing ELND with delayed lymphadenectomy at the time of clinical recurrence. Patients had to have histologically diagnosed skin melanoma without clinically detectable regional lymph node metastases.

Data Extraction: The following information was extracted from each . . . [Full Text of this Article]

Comment

Brown University School of Medicine and Veterans Affairs Medical Center, Providence, RI